Deep Brain Stimulation For Treatment Resistant Major Depression: Neural Correlates And Neuropsychological Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$257,561.00
Summary
Major depression is a prevalent and devastating mental illness. While there are numerous pharmacological and psychological antidepressant therapies available, many patients do not respond to these treatments. Deep Brain Stimulation (DBS) is emerging as a potential treatment option for individuals with chronic severe treatment resistant major depression. The current project will investigate the cognitive and neurobiological outcomes associated with the use of DBS to treat depression.
This Australian-led, investigator initiated and conducted study, is the first and only large scale clinical trial designed to assess the balance of potential benefits and risks of early rapid blood pressure lowering in intracerebral haemorrhage stroke, a disease in which there is still no convincing evidence of benefit from any medical treatment, where the role of surgery remains controversial, and from which the chances of surviving has failed to improve in recent decades.
Seizures And Carbon Dioxide – A Study Of Respiratory Acidosis As A Cause For Seizure Termination And Trial Of Carbogen As An Anti-epileptic
Funder
National Health and Medical Research Council
Funding Amount
$317,582.00
Summary
Although much is known about epilepsy, the reason a seizure stops is not clear. A rise in the acidity of the blood, mainly due to a rise in carbon dioxide from breathing less deeply, may well contribute. Currently the standard treatments given in hospital to stop seizures are sedatives. Although effective, this sedation can need Intensive Care treatment. We aim to develop a safe, rapid, non-sedating way to treat seizures using a small amount of carbon dioxide in oxygen.
Central nervous system cytokines and morphine analgesia. Morphine remains the drug of choice for the management of moderate-to-severe pain, however its clinical effectiveness is compromised by the fact that morphine's analgesic (pain reducing) efficacy becomes less effective the more it is administered.. This project will examine how analgesic tolerance develops from a completely new approach: Namely, how stimulation of the immune system within the central nervous system is a crucial factor in t ....Central nervous system cytokines and morphine analgesia. Morphine remains the drug of choice for the management of moderate-to-severe pain, however its clinical effectiveness is compromised by the fact that morphine's analgesic (pain reducing) efficacy becomes less effective the more it is administered.. This project will examine how analgesic tolerance develops from a completely new approach: Namely, how stimulation of the immune system within the central nervous system is a crucial factor in the development of tolerance. Modulation of analgesia by the immune system has not been systematically studied and provides a potentially fertile ground for the development of new techniques in the management of clinical pain.Read moreRead less
Thrombolysis is a method of dissolving the blood clot that is the cause of the majority of strokes in Australia. The first major trial to demonstrate benefit for this treatment was published some 11 years ago but treatment has not been widely implemented across Australia because of the difficulties in giving treatment within the very tight time window for which treatment is currently approved (patients must get to hospital, be scanned and start treatment within 3 hours of the onset of the stroke ....Thrombolysis is a method of dissolving the blood clot that is the cause of the majority of strokes in Australia. The first major trial to demonstrate benefit for this treatment was published some 11 years ago but treatment has not been widely implemented across Australia because of the difficulties in giving treatment within the very tight time window for which treatment is currently approved (patients must get to hospital, be scanned and start treatment within 3 hours of the onset of the stroke). Other factors which have limited implementation of treatment in Australia are continued debate over the trial data for this treatment as only one of the 5 major trials was positive. In addition, virtually no patients aged over 80 years old were included in the previous trials, and as this age group represents about a third of all stroke in Australia, new data in this age group is required. As a result of the difficulty in giving a treatment within such a tight time window and the ongoing debate about the trial data, few Australians are currently treated and thus the public health impact is negligible. In to change clinical practice, we need reliable data from a large convincing further trial of thrombolysis with the more realistic time window of 6 hours. The Third International Stroke Trial (IST-3) is a large international collaborative effort to determine whether thrombolysis treatment offered to a wider range of patients up to 6 hours from stroke onset results in an increase in long-term independent survival. Data from such a trial is most likely to change clinical practice and lead to an important public health benefit.Read moreRead less
‘Chemobrain’: Neuroimmunological Consequences Of Chemotherapy-induced Mucositis And Opioid Palliation In Development Of The Condition
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Approximately 46% of cancer patients receiving chemotherapy will experience cognitive impairment. The development of this condition may be linked to another common gut side-effect of chemotherapy- mucositis. The treatment of mucositis pain by potent painkillers called opioids may also increase the risk of cognitive change. This project will determine the nervous system changes occurring in mucositis to identify targets for drug intervention to prevent development of cognitive decline.
Cannabidiol (CBD): A Novel Therapeutic For Alzheimer's Disease.
Funder
National Health and Medical Research Council
Funding Amount
$775,005.00
Summary
Current drugs do not stop or reverse the progression of Alzheimer’s disease (AD). Also, brains of AD patients show a number of biological changes and effective drugs should target those together. Cannabidiol (CBD) has such abilities when tested in AD cell models. We found that CBD can also prevent and reverse memory deficits in AD mice. We propose to provide convincing preclinical evidence for the benefits of CBD for human AD therapy and to define mechanisms involved.
Enhanced Control Of Hypertension And Thrombolysis In Stroke Study (STAY ENCHANTED)
Funder
National Health and Medical Research Council
Funding Amount
$2,437,384.00
Summary
"Clot busting" treatment is the only approved medical treatment for the commonest type of stroke, ischaemic stroke. However, uptake of treatment remains poor, mainly due to the known major risk of bleeding in the brain. STAY ENCHANTED is an international clinical trial to investigate whether "clot-busting" can be made safer using a lower dose and/or immediate blood pressure lowering. A safer more effective regime could have a major global health impact.
The Australian, Imaging, Biomarkers And Lifestyle Study Of Ageing (AIBL) Phase III - Facilitating Early Intervention In Preclinical Alzheimer's Disease.
Funder
National Health and Medical Research Council
Funding Amount
$733,653.00
Summary
Amyloid brain scans can detect the onset of Alzheimer's disease 10-15 years before symptoms first appear. Amyloid build-up is thought to be the cause of Alzheimer's disease. The earlier that drugs designed to slow the build up of amyloid or to clear it from the brain are given, the greater the chance of benefit. This study will use the recent discoveries from the Australian AIBL study to develop the best method to find these people with brain amyloid but no symptoms for early treatment trials to ....Amyloid brain scans can detect the onset of Alzheimer's disease 10-15 years before symptoms first appear. Amyloid build-up is thought to be the cause of Alzheimer's disease. The earlier that drugs designed to slow the build up of amyloid or to clear it from the brain are given, the greater the chance of benefit. This study will use the recent discoveries from the Australian AIBL study to develop the best method to find these people with brain amyloid but no symptoms for early treatment trials to prevent dementia.Read moreRead less
REVERSIBLE AND IRREVERSIBLE TNF-MEDIATED COGNITIVE DECLINE
Funder
National Health and Medical Research Council
Funding Amount
$444,460.00
Summary
This proposal seeks to clarify the neuronal mechanisms underlying the inflammatory processing leading to cognitive decline. Furthermore, the research project identifies anti-inflammatory treatment options aiming at improved cognitive performance in people at risk for or suffering from cognitive impairment of neuropsychiatric disorders such as dementia and depression.